Idogen: Production agreement in place - Nordea
"Idogen recently signed a collaboration agreement for production with the Radboud University Medical Center in the Netherlands, a global leader in the field with 20 years of experience in manufacturing cell therapy. The agreement is a step forward in Idogen's journey in bringing its pipeline projects, IDO 8 and IDO T, towards clinical trials (expected to commence in Q1 2021).
During the third quarter, the cost development remained healthy and Idogen reiterated its expectation that its end-of-quarter cash position of SEK 33.8m is sufficient to finance operations until Q3 2020."
Länk till uppdragsanalys nedan.
During the third quarter, the cost development remained healthy and Idogen reiterated its expectation that its end-of-quarter cash position of SEK 33.8m is sufficient to finance operations until Q3 2020."
Länk till uppdragsanalys nedan.
Commissioned research feed